Genmab A GMAB
NASDAQ GMAB
$39.57 +0.50 (+1.28%)
At close: Oct 21, 2026 · 4:00 PM EDT

Genmab A (GMAB) Non-Current Debt (2025 - 2026)

Updated

Genmab A (GMAB) recorded Non-Current Debt of $4.84 billion in the quarter ended Jun 30, 2026, down 1.9% from the prior quarter.

Analysis

Genmab A (GMAB) Non-Current Debt (2025 - 2026) Analysis & Trends

As of Dec 31, 2025, Genmab A reported Non-Current Debt of $5 billion.

  • Annual Non-Current Debt has a five-year compound annual growth rate of 174.3% (years ended Dec 2020 to Dec 2025).
  • Across earlier years, Non-Current Debt came in at $41.02 million in the year ended Dec 31, 2021 (+27.5%).
  • The figure for the quarter ended Jun 30, 2026 is the lowest quarterly Non-Current Debt since the quarter ended Dec 31, 2021.
Peer Set

Peer Comparison

# Company Market Cap Enterprise Value Gross Profit (Qtr) Non-Current Debt (Qtr)
1 Eli Lilly 1,136.97 Bn 1,105.55 Bn 19.71 Bn 47.86 Bn
2 Johnson & Johnson 619.72 Bn 538.25 Bn 17.26 Bn 37.34 Bn
3 AbbVie 503.40 Bn 476.52 Bn 12.70 Bn 62.48 Bn
4 Merck 370.15 Bn 324.53 Bn 12.21 Bn 51.08 Bn
5 Novartis Ag 298.64 Bn 262.63 Bn 11.24 Bn 1.96 Bn
6 Astrazeneca 261.07 Bn 234.76 Bn 12.86 Bn 23.68 Bn
7 Amgen 237.00 Bn 192.40 Bn 7.24 Bn 51.86 Bn
8 Gilead Sciences 191.24 Bn 165.43 Bn 6.22 Bn 23.83 Bn
9 Pfizer 170.31 Bn 116.96 Bn 10.94 Bn 60.50 Bn
10 Genmab A 2.56 Bn -2.81 Bn 1.07 Bn 4.84 Bn
Historic Data

Historic Data

Download Data
DateValue
Jun 30, 2026 4.84 Bn
Mar 31, 2026 4,933.00
Dec 31, 2025 5.00 Bn
API Access

Genmab A Non-Current Debt API

Pull this series into your own models, spreadsheets and apps with the Business Quant Historical Metrics API. The request below matches the chart above — change the frequency, period or values and it follows. Swap YOUR_API_KEY for your own key.

https://data.businessquant.com/historic?slug=non-current-debt&ticker=GMAB&period=max&api_key=YOUR_API_KEY